国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (11): 668-672.doi: 10.3760/cma.j.issn.1673-422X.2019.11.005

• 论著 • 上一篇    下一篇

核糖体结合蛋白1在食管癌中的表达及其临床意义

彭彦才，郝登荣   

  1. 陕西省榆林市第一医院胸心外科719000
  • 出版日期:2019-11-08 发布日期:2019-12-26
  • 通讯作者: 郝登荣 E-mail:hdr1983@163.com

Expression and clinical significance of ribosome-binding protein 1 in esophageal carcinoma

Peng Yancai, Hao Dengrong   

  1. Department of Cardiothoracic Surgery, Yulin First Hospital of Shaanxi Province, Yulin 719000, China
  • Online:2019-11-08 Published:2019-12-26
  • Contact: Hao Dengrong E-mail:hdr1983@163.com

PDF

319

摘要： 目的研究核糖体结合蛋白1（RRBP1）在食管癌中的表达及临床意义。方法选取2010年1月至2014年12月陕西省榆林市第一医院收治的120例食管癌患者的肿瘤组织和癌旁组织，通过实时定量PCR（qRT-PCR）、Western blotting和免疫组织化学法检测RRBP1表达水平。分析RRBP1表达水平与食管癌患者临床病理特征和预后的相关性。结果RRBP1在食管癌组织中的表达量显著高于癌旁组织。在mRNA水平，肿瘤组织相对表达量为3.5±1.3，癌旁组织为1.0±0.3，差异具有统计学意义（t=19.130，P＜0.001）；在蛋白水平，肿瘤组织相对表达量为1.0±0.4，癌旁组织为0.3±0.1，差异具有统计学意义（t=4.225，P＜0.001）；免疫组织化学结果显示，59.2%(71/120)的肿瘤组织表现为RRBP1高表达，而癌旁组织中这一比例下降为11.7%(14/120)，差异具有统计学意义（χ2=59.182，P＜0.001）。RRBP1表达水平与患者淋巴结转移和TNM分期具有相关性（χ2=10.631，P=0.001；χ2=31.212，P＜0.001）。生存分析表明，RRBP1表达水平、淋巴结转移以及TNM分期是评估患者预后的重要指标（χ2=9.455，P=0.006；χ2=14.542，P＜0.001；χ2=11.987，P＜0.001）。Cox回归分析表明，RRBP1高表达（RR=2.441，95%CI为1.267～4.702，P=0.008）、淋巴结有转移（RR=4.024，95%CI为2.180～7.424，P＜0.001）和TNM分期高（RR=3.054，95%CI为1.452～6.421，P=0.003）均是食管癌患者预后不良的危险因素。结论RRBP1在食管癌中高表达，可作为分子标志物评估食管癌患者预后。

关键词: 食管肿瘤, 预后, 生存分析, 核糖体结合蛋白

Abstract: ObjectiveTo investigate the expression and clinical significance of ribosome-binding protein 1 (RRBP1) in esophageal carcinoma. MethodsA total of 120 esophageal carcinoma patients admitted to Yulin First Hospital of Shaanxi Province from January 2010 to December 2014 were enrolled in this study. RRBP1 expression was detected in esophageal carcinoma and matched adjacent normal tissues by real-time quantitative PCR (qRT-PCR), Western blotting and immunohistochemical staining. The relationships of RRBP1 expression with clinicopathological futures and prognosis were statistically analyzed. ResultsRRBP1 expression level was significantly higher in esophageal carcinoma tissues compared with matched adjacent normal tissues. In the mRNA level, the relative quantitative expression in tumor tissues was 3.5±1.3, and 1.0±0.3 in adjacent normal tissues, with a significant difference (t=19.130, P＜0.001). In the protein level, the relative quantitative expression in tumor tissues was 1.0±0.4, and 0.3±0.1 in adjacent normal tissues, with a significant difference (t=4.225, P＜0.001). The immunohistochemical results showed that RRBP1 high expression was found in 71 (59.2%) tumor tissues, and the proportion dropped to 11.7% (14/120) in adjacent normal tissues, with a significant difference (χ2=59.182, P＜0.001). In addition, RRBP1 expression was correlated with lymph node metastasis and TNM stage (χ2=10.631, P=0.001; χ2=31.212, P＜0.001). Survival analysis revealed that RRBP1 expression, lymph node metastasis and TNM stage were significantly correlated with patients′ prognosis (χ2=9.455, P=0.006; χ2=14.542, P＜0.001; χ2=11.987, P＜0.001). Cox regression analysis showed that high expression of RRBP1 (RR=2.441, 95%CI: 1.267-4.702, P=0.008), lymph node metastasis (RR=4.024, 95%CI: 2.180-7.424, P＜0.001) and high TNM stage (RR=3.054, 95%CI: 1.452-6.421, P=0.003) were the risk factors for poor prognosis of esophageal carcinoma patients. ConclusionRRBP1 is highly expressed in esophageal carcinoma and can serve as a potential biomarker to predict patients′ prognosis.

Key words: Esophageal neoplasms, Prognosis, Survival analysis, Ribosome-binding protein 1